Abstract
The severity of SARS-CoV2 infection, Covid19 disease, should account for the diversity of human individual immunoinflammatory responses. Serum immunological markers during Covid19 illness may lead to individualized therapeutics with better outcomes. Efficient treatment for Covid19 may require: 1) early disease detection, 2) combineddrug therapy for 3) targeting the virus replication cycle, and 4) individualized drug treatment for specific immunoinflammatory human profile responses administered in a 5) timely manner. Covid19 is unlikely to be the last emergent human disease with fast pandemic potential. Gathering knowledge on the individual human host profilesof immunoinflammatory responses is an opportunity that could lead us to understand individual differences in response to infection at the individual and population level, paving the way to faster, more efficient strategies to tackle upcoming infectious diseases. This is a position paper based on an integrative non-exhaustive literature revision.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call